低剂量布地奈德吸入对轻度哮喘患者PC20 AMP水平的影响：3个月的随访研究
2009/06/24
单磷酸腺苷（AMP）为哮喘的一个诊断指标。本研究主要评价低剂量布地奈德（IB）对PC20 AMP水平的影响。对17名处于稳定期的轻度哮喘患者进行前瞻性研究。基础状态检测后，给予患者400 mg布地奈德吸入治疗。治疗后12小时及第5、15、30和90天检测患者的AMP水平。治疗后12小时47％的患者AMP检测阴性。
本研究显示，低剂量IB治疗可在12小时内恢复气道反应性，因此AMP水平可以作为监测治疗过程的有效指标。
本研究显示，低剂量IB治疗可在12小时内恢复气道反应性，因此AMP水平可以作为监测治疗过程的有效指标。
（苏楠 审校）
Kokturk N,et al. J Asthma. 2009 Apr;46(3):259-264
The effect of low-dose inhaled budesonide on PC20 AMP levels in patients with mild asthma: a 3-month follow-up study.
Adenosine monophosphate (AMP) challenge is a diagnostic tool for asthma. The aim of this study is to evaluate the effect of low dose inhaled budesonide (IB) on PC(20)AMP levels. Seventeen stable mild asthmatic patients were prospectively recruited. After initial testing, patients were administered 400 microg of inhaled budesonide. AMP challenge was then repeated at the 12th hour and 5th,15th, 30th, and 90th days of the treatment. AMP challenge resulted in negative in 47% of the patients at 12(-)hour testing. This study suggests that low-dose IB may return airway responsiveness as early as 12 hours and AMP challenge may be effectively used for treatment monitorization.
上一篇：
使用福莫特罗和吸入糖皮质激素对慢性哮喘进行常规治疗：严重副作用
下一篇：
高分辨率CT扫描显示采用常规治疗的哮喘患者气道重构具有不可逆性：6年的纵向研究
